|
AU2013200039A1
|
|
Disease modifying anti-arthritic activity of 2-methoxyestradiol
|
|
WO2008094665A1
|
|
Method of treating amyloidosis mediated diseases
|
|
AU2007234536A1
|
|
Compositions comprising purified 2-methoxyestradiol and methods of producing same
|
|
CA2646065A1
|
|
Disease modifying anti-arthritic activity of 2-methoxyestradiol
|
|
AU2007200470A1
|
|
Antiangiogenic Agents
|
|
WO2007076055A2
|
|
Compositions and methods comprising proteinase activated receptor antagonists
|
|
WO2007059111A2
|
|
Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
|
|
EP1819343A2
|
|
A method of administering anti-angiogenic agents and a method of treating disease using same
|
|
US2006025619A1
|
|
Methods of using 2-methoxyestradiol of high purity
|
|
AU2005211579B8
|
|
Compositions comprising purified 2-methoxyestradiol and methods of producing same
|
|
WO2005089256A2
|
|
Antiangiogenic agents
|
|
WO2005051357A1
|
|
Antiangiogenic agents
|
|
EP1633367A2
|
|
Antiangiogenic agents
|
|
WO2004002418A2
|
|
Compositions and methods comprising protein activated receptor antagonists
|
|
WO03073985A2
|
|
New methods of using antiangiogenic agents
|
|
AU2003209439A1
|
|
Non-steroidal analogs of 2-methoxyestradiol
|
|
AU2002323063B2
|
|
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US6723536B2
|
|
Method of producing and purifying angiostatin
|
|
WO0230982A2
|
|
Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
|
|
US7135581B2
|
|
Antiangiogenic agents
|
